These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 23926462)

  • 1. Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.
    Blum K; Oscar-Berman M; Stuller E; Miller D; Giordano J; Morse S; McCormick L; Downs WB; Waite RL; Barh D; Neal D; Braverman ER; Lohmann R; Borsten J; Hauser M; Han D; Liu Y; Helman M; Simpatico T
    J Addict Res Ther; 2012 Nov; 3(5):139. PubMed ID: 23926462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.
    Blum K; Simpatico T; Badgaiyan RD; Demetrovics Z; Fratantonio J; Agan G; Febo M; Gold MS
    J Reward Defic Syndr; 2015; 1(2):75-80. PubMed ID: 27617300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map.
    Chen TJ; Blum K; Chen AL; Bowirrat A; Downs WB; Madigan MA; Waite RL; Bailey JA; Kerner M; Yeldandi S; Majmundar N; Giordano J; Morse S; Miller D; Fornari F; Braverman ER
    J Psychoactive Drugs; 2011; 43(2):108-27. PubMed ID: 21858957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation.
    Blum K; Oscar-Berman M; Giordano J; Downs B; Simpatico T; Han D; Femino J
    J Genet Syndr Gene Ther; 2012 Oct; 3(4):. PubMed ID: 23264886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).
    Blum K; Oscar-Berman M; Demetrovics Z; Barh D; Gold MS
    Mol Neurobiol; 2014 Dec; 50(3):765-96. PubMed ID: 24878765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction.
    Blum K; Badgaiyan RD; Agan G; Fratantonio J; Simpatico T; Febo M; Haberstick BC; Smolen A; Gold MS
    J Reward Defic Syndr; 2015; 1(1):65-68. PubMed ID: 26052557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).
    Kenneth B; Edward MJ; Marjorie GLC; David B; Bruce S; Panayotis TK; William DB; Davis S; Lisa L; Eric BR; Mark M; David M; Lyle F; Rajendra BD
    CPQ Neurol Psychol; 2018; 1(2):. PubMed ID: 30957097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis.
    Blum K; Gold MS
    Med Hypotheses; 2011 Apr; 76(4):576-84. PubMed ID: 21306831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS).
    Blum K; Baron D; McLaughlin T; Gold MS
    J Neurol Sci; 2020 Apr; 411():116733. PubMed ID: 32088516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine Genetics and Function in Food and Substance Abuse.
    Blum K; Oscar-Berman M; Barh D; Giordano J; Gold M
    J Genet Syndr Gene Ther; 2013 Feb; 4(121):. PubMed ID: 23543775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.
    Blum K; Chen AL; Chen TJ; Braverman ER; Reinking J; Blum SH; Cassel K; Downs BW; Waite RL; Williams L; Prihoda TJ; Kerner MM; Palomo T; Comings DE; Tung H; Rhoades P; Oscar-Berman M
    Theor Biol Med Model; 2008 Nov; 5():24. PubMed ID: 19014506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape.
    Blum K; Febo M; Badgaiyan RD; Demetrovics Z; Simpatico T; Fahlke C; M OB; Li M; Dushaj K; Gold MS
    Curr Neuropharmacol; 2017; 15(1):184-194. PubMed ID: 27174576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
    Blum K; Dennen CA; Elman I; Bowirrat A; Thanos PK; Badgaiyan RD; Downs BW; Bagchi D; Baron D; Braverman ER; Gupta A; Green R; McLaughlin T; Barh D; Gold MS
    J Pers Med; 2022 Oct; 12(10):. PubMed ID: 36294858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
    Gilley ED; Bowirrat A; Gupta A; Giordano J; A Dennen C; R Braverman E; D Badgaiyan R; McLaughlin T; Baron D; Blum K
    Curr Pharm Biotechnol; 2023 Apr; ():. PubMed ID: 37102488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land?
    Blum K; Thanos PK; Badgaiyan RD; Febo M; Oscar-Berman M; Fratantonio J; Demotrovics Z; Gold MS
    Expert Opin Biol Ther; 2015 Jul; 15(7):973-85. PubMed ID: 25974314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).
    Blum K; Bowirrat A; Baron D; Lott L; Ponce JV; Brewer R; Siwicki D; Boyett B; Gondre-Lewis MC; Smith DE; Panayotis K T; Badgaiyan S; Hauser M; Fried L; A R; Downs BW; Badgaiyan RD
    J Syst Integr Neurosci; 2020 Aug; 6(2):. PubMed ID: 33614164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?
    Gold MS; Baron D; Bowirrat A; Blum K
    J Neurol Sci; 2020 Nov; 418():117137. PubMed ID: 32957037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility.
    Blum K; Hauser M; Fratantonio J; Badgaiyan RD
    Addict Genet; 2015 Jul; 2(1):1-5. PubMed ID: 26807291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.
    Miller DK; Bowirrat A; Manka M; Miller M; Stokes S; Manka D; Allen C; Gant C; Downs BW; Smolen A; Stevens E; Yeldandi S; Blum K
    Postgrad Med; 2010 Nov; 122(6):188-213. PubMed ID: 21084795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Shared Molecular and Genetic Basis for Food and Drug Addiction: Overcoming Hypodopaminergic Trait/State by Incorporating Dopamine Agonistic Therapy in Psychiatry.
    Gold MS; Badgaiyan RD; Blum K
    Psychiatr Clin North Am; 2015 Sep; 38(3):419-62. PubMed ID: 26300032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.